Literature DB >> 12388700

Effective postexposure treatment of retrovirus-induced disease with immunostimulatory DNA containing CpG motifs.

Anke R M Olbrich1, Simone Schimmer, Klaus Heeg, Koen Schepers, Ton N M Schumacher, Ulf Dittmer.   

Abstract

Therapeutic strategies for the treatment of acute retroviral infections have relied mainly on antiviral drugs. In this study we used the Friend virus model system to demonstrate that enhancement of the immune system can also have dramatic therapeutic effects. Since resistance to Friend virus-induced leukemia in mice is associated with T helper cell type 1 (Th1) immune responses, we enhanced these responses in susceptible mice by treatment with synthetic oligodeoxynucleotides containing unmethylated CpG motifs (CpG-ODN). Treatments begun at 4 days postinfection increased recovery from 6% in the control group to 74% in the CpG-treated group. CpG-mediated recovery was associated with a significant reduction of viral loads in the blood and spleens of treated mice compared to those of control animals. The treatment promoted Th1-type cytokine production by splenocytes of Friend virus-infected mice and augmented Friend virus-specific cytotoxic T-cell responses, but no influence on the virus-specific neutralizing antibody response was observed. Friend virus-specific CD8(+) T cells were critical for effective treatment with CpG-ODN, since in vivo depletion of these cells from treated mice prevented their recovery. Our results demonstrate that CpG-ODN therapy can significantly enhance virus-specific cellular immune responses and prevent retrovirus-induced disease. These findings may have implications for antiviral therapy in general.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12388700      PMCID: PMC136771          DOI: 10.1128/jvi.76.22.11397-11404.2002

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  42 in total

1.  Kinetics of the development of protective immunity in mice vaccinated with a live attenuated retrovirus.

Authors:  U Dittmer; B Race; K J Hasenkrug
Journal:  J Virol       Date:  1999-10       Impact factor: 5.103

Review 2.  The role of CD4 and CD8 T cells in recovery and protection from retroviral infection: lessons from the Friend virus model.

Authors:  K J Hasenkrug; U Dittmer
Journal:  Virology       Date:  2000-07-05       Impact factor: 3.616

3.  Bacterial CpG-DNA activates dendritic cells in vivo: T helper cell-independent cytotoxic T cell responses to soluble proteins.

Authors:  T Sparwasser; R M Vabulas; B Villmow; G B Lipford; H Wagner
Journal:  Eur J Immunol       Date:  2000-12       Impact factor: 5.532

4.  Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo.

Authors:  G Hartmann; R D Weeratna; Z K Ballas; P Payette; S Blackwell; I Suparto; W L Rasmussen; M Waldschmidt; D Sajuthi; R H Purcell; H L Davis; A M Krieg
Journal:  J Immunol       Date:  2000-02-01       Impact factor: 5.422

5.  Role of natural killer cells in resistance against friend retrovirus-induced leukemia.

Authors:  N Iwanami; A Niwa; Y Yasutomi; N Tabata; M Miyazawa
Journal:  J Virol       Date:  2001-04       Impact factor: 5.103

6.  The potential of oligodeoxynucleotides as mucosal and parenteral adjuvants.

Authors:  M J McCluskie; R D Weeratna; H L Davis
Journal:  Vaccine       Date:  2001-03-21       Impact factor: 3.641

7.  Role of interleukin-4 (IL-4), IL-12, and gamma interferon in primary and vaccine-primed immune responses to Friend retrovirus infection.

Authors:  U Dittmer; K E Peterson; R Messer; I M Stromnes; B Race; K J Hasenkrug
Journal:  J Virol       Date:  2001-01       Impact factor: 5.103

8.  Major histocompatibility complex class I gene controls the generation of gamma interferon-producing CD4(+) and CD8(+) T cells important for recovery from friend retrovirus-induced leukemia.

Authors:  K E Peterson; M Iwashiro; K J Hasenkrug; B Chesebro
Journal:  J Virol       Date:  2000-06       Impact factor: 5.103

9.  Enhanced cellular immune response and reduced CD8(+) lymphocyte apoptosis in acutely SIV-infected Rhesus macaques after short-term antiretroviral treatment.

Authors:  M Spring; C Stahl-Hennig; N Stolte; N Bischofberger; J Heeney; K Tenner-Ràcz; P Ràcz; D Lorenzen; G Hunsmann; U Dittmer
Journal:  Virology       Date:  2001-01-05       Impact factor: 3.616

Review 10.  The immunobiology and clinical potential of immunostimulatory CpG oligodeoxynucleotides.

Authors:  G J Weiner
Journal:  J Leukoc Biol       Date:  2000-10       Impact factor: 4.962

View more
  13 in total

1.  A point of view: HIV-1/AIDS is an allergy but CpG ODN treatments may inhibit virus replication and reactivate the adaptive immunity--hypothesis and implications.

Authors:  Yechiel Becker
Journal:  Virus Genes       Date:  2005-01       Impact factor: 2.332

2.  The Toll-like receptor 7 (TLR7) agonist, imiquimod, and the TLR9 agonist, CpG ODN, induce antiviral cytokines and chemokines but do not prevent vaginal transmission of simian immunodeficiency virus when applied intravaginally to rhesus macaques.

Authors:  Yichuan Wang; Kristina Abel; Katherine Lantz; Arthur M Krieg; Michael B McChesney; Christopher J Miller
Journal:  J Virol       Date:  2005-11       Impact factor: 5.103

3.  CpG oligodeoxynucleotides block human immunodeficiency virus type 1 replication in human lymphoid tissue infected ex vivo.

Authors:  Erika Schlaepfer; Annette Audigé; Barbara von Beust; Vania Manolova; Markus Weber; Helene Joller; Martin F Bachmann; Thomas M Kundig; Roberto F Speck
Journal:  J Virol       Date:  2004-11       Impact factor: 5.103

4.  Preinfection treatment of resistant mice with CpG oligodeoxynucleotides renders them susceptible to friend retrovirus-induced leukemia.

Authors:  Anke R M Olbrich; Simone Schimmer; Ulf Dittmer
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

5.  The level of friend retrovirus replication determines the cytolytic pathway of CD8+ T-cell-mediated pathogen control.

Authors:  Gennadiy Zelinskyy; Sandra Balkow; Simone Schimmer; Tanja Werner; Markus M Simon; Ulf Dittmer
Journal:  J Virol       Date:  2007-08-29       Impact factor: 5.103

Review 6.  Antiinfective applications of toll-like receptor 9 agonists.

Authors:  Arthur M Krieg
Journal:  Proc Am Thorac Soc       Date:  2007-07

7.  TLR ligand induced IL-6 counter-regulates the anti-viral CD8(+) T cell response during an acute retrovirus infection.

Authors:  Weimin Wu; Kirsten K Dietze; Kathrin Gibbert; Karl S Lang; Mirko Trilling; Huimin Yan; Jun Wu; Dongliang Yang; Mengji Lu; Michael Roggendorf; Ulf Dittmer; Jia Liu
Journal:  Sci Rep       Date:  2015-05-21       Impact factor: 4.379

8.  Amphipathic DNA polymers exhibit antiviral activity against systemic murine Cytomegalovirus infection.

Authors:  Rhonda D Cardin; Fernando J Bravo; Andrea P Sewell; James Cummins; Louis Flamand; Jean-Marc Juteau; David I Bernstein; Andrew Vaillant
Journal:  Virol J       Date:  2009-12-02       Impact factor: 4.099

Review 9.  CpG ODNs treatments of HIV-1 infected patients may cause the decline of transmission in high risk populations - a review, hypothesis and implications.

Authors:  Yechiel Becker
Journal:  Virus Genes       Date:  2005-03       Impact factor: 2.198

10.  Broad-spectrum drugs against viral agents.

Authors:  Mary E Christopher; Jonathan P Wong
Journal:  Int J Mol Sci       Date:  2008-09-01       Impact factor: 6.208

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.